Latest News

7/24/09 AMS and PET in Microdose studies - International Clinical Trials August 2009

Date Posted: 24 Jul 2009 Summary: Studying drug disposition and pharmacokinetics with PET and AMS offers numerous benefits; Graham Lappin and Marie Simpson of Xceleron and Oliver Langer of the Department of Clinical Pharmacology, the Medical University of Vienna, report their findings. Download:  AMS-PET International Clinical Trials Summer 2009.pdf Download

"Positron emission tomography (PET) and accelerator mass spectrometry (AMS) are ultra-sensitive analytical techniques that have been used in human microdose studies. A microdose (or human Phase 0) study is performed at a very early stage of drug development in order to obtain preliminary data on a drug candidate in humans prior to commencement of Phase I clinical trials."

"It is now possible to combine a single clinical study so that PET imaging can be obtained along with pharmacokinetic data, thus maximising the data output from a single trial. Such an approach has the potential to be a far more cost-effective design than conducting these types of studies in individual groups of subjects."

Please download the article to read more.

This article appeared in International Clinical Trials, August 2009, http://www.samedanltd.com/

Click to see more news